Vaccine to cost Rs 219-292 to Govt; double price in pvt market, says SII
   Date :05-Jan-2021

Vaccine _1  H x
Enough stockpile of COVID-19 vaccine for inoculation, says Niti Aayog
CORONAVIRUS vaccine developed by AstraZeneca and the University of Oxford will cost USD 3-4 per shot (Rs 219-292) to the Government and will be priced at double that rate in private market ones such sales open up, said the CEO of its Indian manufacturer on Monday. Serum Institute of India, the world’s largest vaccine manufacturer, has a licence to produce the shot and has already manufactured close to 50 million doses. Its CEO Adar Poonawalla told PTI that the company will start selling the Covishield to the Indian Government and GAVI countries in the first stage, followed by the private market.
“We want the vaccine to be affordable and accessible to all. The Government of India will receive it at a far more affordable price of USD 3-4, since they will be buying in a larger volume,” he said. Poonawalla, who had taken a huge gamble once the pandemic began to unfold by overhauling Serum’s assembly line and “sacrificing” products that were to be destined for Europe and America in anticipation of a COVID-19 vaccine, said the priority supplies will go to India and the GAVI (Global Alliance for Vaccines and Immunisation) nations.
Only after meeting their requirements, “the private market will open up where the pricing would be USD 6-8 per done,” he said. Serum will have 100 million doses in a month, and will possibly double it by April. The Government has indicated that it may need 300 million doses before July 2021, with frontline health workers and the elderly given priority. Poonawalla said Serum was in touch with the Government for the vaccine’s procurement. “Initially, we will supply 50 million doses and we will get more confirmations over the course of the next few days,” he added. After the regulator’s nod, Serum expects formalities to be completed in the next 7 to 10 days for the rollout to begin.